Full Text View
Tabular View
No Study Results Posted
Related Studies
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
This study is currently recruiting participants.
Verified December 2011 by University of Pittsburgh
Study NCT01488318   Information provided by University of Pittsburgh

First Received on November 30, 2011.   Last Updated on December 6, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Squamous Cell
Head and Neck Neoplasms
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplasms, Squamous Cell
Interventions listed in this trial
Cetuximab
Dasatinib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
University of Pittsburgh
Bristol-Myers Squibb


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services